187 related articles for article (PubMed ID: 26579772)
1. Potential Application of Alchemical Free Energy Simulations to Discriminate GPCR Ligand Efficacy.
Lee HS; Seok C; Im W
J Chem Theory Comput; 2015 Mar; 11(3):1255-66. PubMed ID: 26579772
[TBL] [Abstract][Full Text] [Related]
2. Design of Drug Efficacy Guided by Free Energy Simulations of the β
Panel N; Vo DD; Kahlous NA; Hübner H; Tiedt S; Matricon P; Pacalon J; Fleetwood O; Kampen S; Luttens A; Delemotte L; Kihlberg J; Gmeiner P; Carlsson J
Angew Chem Int Ed Engl; 2023 May; 62(22):e202218959. PubMed ID: 36914577
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.
Goetz A; Lanig H; Gmeiner P; Clark T
J Mol Biol; 2011 Dec; 414(4):611-23. PubMed ID: 22037586
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective binding of agonists to the β
Plazinska A; Plazinski W
Mol Biosyst; 2017 May; 13(5):910-920. PubMed ID: 28338133
[TBL] [Abstract][Full Text] [Related]
7. DIRECT-ID: An automated method to identify and quantify conformational variations--application to β2 -adrenergic GPCR.
Lakkaraju SK; Lemkul JA; Huang J; MacKerell AD
J Comput Chem; 2016 Feb; 37(4):416-25. PubMed ID: 26558323
[TBL] [Abstract][Full Text] [Related]
8. Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.
Zhu Y; Yuan Y; Xiao X; Zhang L; Guo Y; Pu X
J Mol Model; 2014 Nov; 20(11):2491. PubMed ID: 25342155
[TBL] [Abstract][Full Text] [Related]
9. Conformational and Thermodynamic Landscape of GPCR Activation from Theory and Computation.
Dong SS; Goddard WA; Abrol R
Biophys J; 2016 Jun; 110(12):2618-2629. PubMed ID: 27332120
[TBL] [Abstract][Full Text] [Related]
10. Insights into the role of Asp79(2.50) in β2 adrenergic receptor activation from molecular dynamics simulations.
Ranganathan A; Dror RO; Carlsson J
Biochemistry; 2014 Nov; 53(46):7283-96. PubMed ID: 25347607
[TBL] [Abstract][Full Text] [Related]
11. Ligand-binding affinity of alternative conformers of human β
Dilcan G; Doruker P; Akten ED
Chem Biol Drug Des; 2019 May; 93(5):883-899. PubMed ID: 30637937
[TBL] [Abstract][Full Text] [Related]
12. Characterizing clinically relevant natural variants of GPCRs using computational approaches.
Sengupta D; Sonar K; Joshi M
Methods Cell Biol; 2017; 142():187-204. PubMed ID: 28964336
[TBL] [Abstract][Full Text] [Related]
13. Mapping the functional binding sites of cholesterol in β2-adrenergic receptor by long-time molecular dynamics simulations.
Cang X; Du Y; Mao Y; Wang Y; Yang H; Jiang H
J Phys Chem B; 2013 Jan; 117(4):1085-94. PubMed ID: 23298417
[TBL] [Abstract][Full Text] [Related]
14. Search for β2 adrenergic receptor ligands by virtual screening via grid computing and investigation of binding modes by docking and molecular dynamics simulations.
Bai Q; Shao Y; Pan D; Zhang Y; Liu H; Yao X
PLoS One; 2014; 9(9):e107837. PubMed ID: 25229694
[TBL] [Abstract][Full Text] [Related]
15. The dynamic process of β(2)-adrenergic receptor activation.
Nygaard R; Zou Y; Dror RO; Mildorf TJ; Arlow DH; Manglik A; Pan AC; Liu CW; Fung JJ; Bokoch MP; Thian FS; Kobilka TS; Shaw DE; Mueller L; Prosser RS; Kobilka BK
Cell; 2013 Jan; 152(3):532-42. PubMed ID: 23374348
[TBL] [Abstract][Full Text] [Related]
16. Fast, metadynamics-based method for prediction of the stereochemistry-dependent relative free energies of ligand-receptor interactions.
Plazinska A; Plazinski W; Jozwiak K
J Comput Chem; 2014 Apr; 35(11):876-82. PubMed ID: 24615679
[TBL] [Abstract][Full Text] [Related]
17. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
Saleh N; Ibrahim P; Clark T
Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
[TBL] [Abstract][Full Text] [Related]
18. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors.
Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD
J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383
[TBL] [Abstract][Full Text] [Related]
19. Modeling GPCR active state conformations: the β(2)-adrenergic receptor.
Simpson LM; Wall ID; Blaney FE; Reynolds CA
Proteins; 2011 May; 79(5):1441-57. PubMed ID: 21337626
[TBL] [Abstract][Full Text] [Related]
20. Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules.
Gandhimathi A; Sowdhamini R
J Biomol Struct Dyn; 2016 May; 34(5):952-70. PubMed ID: 26327576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
